ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said Chairman and Chief Executive Tian Wenzhi acquired 50,000 H shares in the open market on Friday at an average price of HK$7.95 per share, according to a same-day Hong Kong bourse filing.

Shares of the firm were up nearly 2% in Monday's mid-day trade.

Following the purchase, Tian holds nearly 116.1 million shares, representing 26.9% of the company's issued share capital.